Cannabidiol for cannabis use disorder: too high hopes? – Authors' reply
Authors:
- 1 October 2020
- journal article
- letter
- Published by Elsevier in The Lancet Psychiatry
- Vol. 7 (10) , 840
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trialThe Lancet Psychiatry, 2020
- The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agendaDrug and Alcohol Dependence, 2020
- Nabiximols for the Treatment of Cannabis DependenceJAMA Internal Medicine, 2019
- Nabiximols combined with motivational enhancement/cognitive behavioral therapy for the treatment of cannabis dependence: A pilot randomized clinical trialPLOS ONE, 2018
- Nabiximols as an Agonist Replacement Therapy During Cannabis WithdrawalJAMA Psychiatry, 2014